Song Su Jung, Pandolfi Pier Paolo
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Curr Opin Hematol. 2014 Jul;21(4):276-82. doi: 10.1097/MOH.0000000000000054.
This review highlights recent insights into the roles of microRNAs (miRNAs) in pathogenesis of myeloid malignancies and tantalising prospects of miRNA therapy.
New roles for miRNAs in biological and disease processes are constantly being discovered. Although great effort has been put into identifying and cataloguing aberrantly expressed miRNAs in leukaemia, very little is known about the functional consequences of their deregulation in myeloid malignancies. This review will discuss the significance of powerful oncogenic miRNAs such as miR-22 in self-renewal and transformation of haematopoietic stem cells, as well as their ability to induce epigenetic alterations in the pathogenesis of the stem cell disorder myelodysplastic syndromes and myeloid leukaemia.
Improved understanding of biological roles of miRNAs in the pathogenesis of haematological malignancies will allow rational stratification of patients and provide new therapeutic entries for the treatment of myelodysplastic syndromes and leukaemia.
本综述重点介绍了近年来对微小RNA（miRNA）在髓系恶性肿瘤发病机制中的作用以及miRNA治疗诱人前景的新见解。
miRNA在生物和疾病过程中的新作用不断被发现。尽管人们付出了巨大努力来鉴定和编目白血病中异常表达的miRNA，但对于它们在髓系恶性肿瘤中失调的功能后果却知之甚少。本综述将讨论强大的致癌miRNA，如miR-22在造血干细胞自我更新和转化中的意义，以及它们在干细胞疾病骨髓增生异常综合征和髓系白血病发病机制中诱导表观遗传改变的能力。
更好地理解miRNA在血液系统恶性肿瘤发病机制中的生物学作用，将有助于对患者进行合理分层，并为骨髓增生异常综合征和白血病的治疗提供新的治疗切入点。
